Interferon-α2b zur Therapie des Bindehautmelanoms
- 181 Downloads
- 1 Citations
Zusammenfassung
Eine 71-jährige Patientin mit Zustand nach mehrfacher Bindehautexzision in den 1970er-Jahren bei histologisch gesicherten Bindehautmelanomrezidiven sowie mehrfachen Therapiezyklen mit Mitomycin C stellte sich mit einer zunehmenden Bindehautpigmentierung vor. Die Therapie erfolgte mittels Interferon-α2b-Augentropfen über mehrere Monate 4- bis 5-mal täglich. Hierunter zeigt sich ein vollständiges Verschwinden der Pigmentierung ohne Nebenwirkungen.
Schlüsselwörter
Applikation, topisch Konjunktivale Neoplasie Interferon-α2b Melanom BindehautpigmentierungInterferon alpha 2b for treatment of conjunctival melanoma
Abstract
A 71-year-old female patient with a status following multiple conjunctival excisions, histopathologically confirmed conjunctival melanoma (CMM) and also multiple therapy with mitomycin C presented with progressive conjunctival pigmentation. Treatment was carried out with local interferon α2b administration four or five times daily for several months. The lesion showed regression and lost pigmentation without any side effects.
Keywords
Administration, topical Conjunctival pigmentation Conjunctival neoplasms Interferon alpha-2b MelanomaNotes
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Literatur
- 1.De Potter P, Shields CL et al (1993) Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol 77(10):624–630CrossRefGoogle Scholar
- 2.Demirci H, McCormick SA et al (2000) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol 118(7):885–891PubMedGoogle Scholar
- 3.Finger PT, Sedeek RW et al (2008) Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol 145(1):124–129PubMedCrossRefGoogle Scholar
- 4.Herold TR, Hintschich C (2010) Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol 248(1):111–115PubMedCrossRefGoogle Scholar
- 5.Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34–55PubMedCrossRefGoogle Scholar
- 6.Kim JW, Abramson DH (2008) Topical treatment options for conjunctival neoplasms. Clin Ophthalmol 2(3):503–515PubMedCrossRefGoogle Scholar
- 7.Kirkwood JM, Strawderman MH et al (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7–17PubMedGoogle Scholar
- 8.Kobayashi A, Yoshita T et al (2002) Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b. Jpn J Ophthalmol 46(2):215–217PubMedCrossRefGoogle Scholar
- 9.Kurli M, Finger PT (2005) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years‘ experience. Graefes Arch Clin Exp Ophthalmol 243(11):1108–1114PubMedCrossRefGoogle Scholar
- 10.Shields CL, Shields JA et al (2000) Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 118(11):1497PubMedCrossRefGoogle Scholar
- 11.Vann RR, Karp CL (1999) Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. Ophthalmology 106(1):91–97PubMedCrossRefGoogle Scholar
- 12.Werschnik C, Lommatzsch PK (2002) Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol 25(3):248–255PubMedCrossRefGoogle Scholar